Company intelligence / Profile preview

Synthelia Organics

Ownership: Private
Development stage: Other

Overview

Synthelia Organics provides synthetic chemistry solutions to the pharmaceutical and biotech industries, specializing in custom synthesis, process development, flow chemistry, route optimization, and scale-up from milligram to kilogram quantities. The company has developed proprietary flow reactors and has experience with advanced nanomaterials such as gold nanoparticles for diagnostics. It also contributed to COVID‑19 detection technology using AuNPs. The team includes experienced PhDs/MScs with backgrounds from major pharma companies.

Modalities: Small moleculeNanoparticle (specifically gold nanoparticles/AuNP)Oligonucleotide (via siRNA conjugation to nanoparticles)Peptides/oligomers (via nanoparticle modification)
Industry: Drug Discovery Services

Partnerships

IMDEA Nanociencia collaboration for nanoparticle synthesis/modification

Beyond the preview

Go deeper on Synthelia Organics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synthelia Organics.

Explore the full profile